Clinical Features and Treatment Outcomes of Large Bladder Tumors Nearly Filling the Bladder
Urology Journal,
Vol. 23 No. 02 (2026),
20 June 2026
,
Page 48-53
https://doi.org/10.22037/uj.v23i00.8655
Abstract
Purpose: The prognosis and clinical management of bladder tumors nearly occupying the entire bladder cavity remain poorly defined due to limited available data. This study aimed to evaluate the clinical features and treatment outcomes of patients presenting with bladder tumors nearly filling the bladder at initial diagnosis.
Materials and Methods: After obtaining ethical approval, a retrospective analysis was conducted on 51 patients diagnosed between 2017 and 2024 with primary bladder tumors nearly filling the bladder. All underwent transurethral resection of bladder tumor (TURBT). The clinical and pathological data were analyzed using descriptive statistics and multivariable logistic regression.
Results: The mean age was 76.24 ± 11.7 years, with a median follow-up of 9.73 months (range: 3–84 months). Hematuria was the most frequent symptom (74.5%). Muscle-invasive disease was identified in 43.1% of cases at initial diagnosis, exceeding the 25% generally reported in newly diagnosed bladder cancer cohorts (p < .001). Complete resection was achieved in 68.6%, while 31.4% required repeat TURBT (re-TURBT). Among patients initially diagnosed with non-muscle-invasive tumors, 31.1% were found to have muscle invasion upon second resection. Treatments comprised intravesical immunotherapy (48.6%), radical cystectomy (25.7%), chemoradiation (14.3%), and systemic chemotherapy (11.4%).
Conclusion: Bladder tumors nearly filling the bladder cavity are associated with high rates of muscle invasion and pose significant challenges in treatment and management. Larger, prospective multicenter studies are warranted to validate these findings and optimize management in this high-risk population.
- tumor
- bladder
- cancer
How to Cite
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–63. https://doi.org/10.3322/caac.21834.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49. https://doi.org/10.3322/caac.21820.
Türkiye Kanser İstatistikleri 2019 n.d. https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri (accessed March 14, 2025).
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 2022;81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010.
Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol 2006;49:466–77. https://doi.org/10.1016/j.eururo.2005.12.031.
Tully KH, Moschini M, von Rundstedt F-CE, Aziz A, Kluth LA, Necchi A, et al. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. Urol Oncol Semin Orig Investig 2020;38:851.e19-851.e25. https://doi.org/10.1016/j.urolonc.2020.06.034.
Jia Y, Wu K, Li X. Association between tumor size and prognosis in bladder cancer: novel classifications and insights from a SEER database analysis. Front Surg 2024;11. https://doi.org/10.3389/fsurg.2024.1489832.
Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63:45–57. https://doi.org/10.1016/j.eururo.2012.08.009.
Utku Can ED. The Effect of Bladder Outlet Obstruction on Bladder Cancer Recurrence and Progression 2025. https://doi.org/10.4274/jus.galenos.2024.2024-10-6.
Yang Z, Bai Y, Liu M, Hu X, Han P. Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer:A population-based study. Cancer Med 2020;9:9303–14. https://doi.org/10.1002/cam4.3535.
Tully KH, Moschini M, von Rundstedt F-CE, Aziz A, Kluth LA, Necchi A, et al. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. Urol Oncol 2020;38:851.e19-851.e25. https://doi.org/10.1016/j.urolonc.2020.06.034.
Gellert LL, Warrick J, Al-Ahmadie HA. Urothelial carcinoma with squamous differentiation--the pathologists׳ perspective. Urol Oncol 2015;33:437–43. https://doi.org/10.1016/j.urolonc.2015.07.018.
Aslan S, Tasdemir MN, Cakir E, Oguz U, Tok B. Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS). Abdom Radiol 2025. https://doi.org/10.1007/s00261-025-04852-9.
Nallabothula AK, Mudunuri HVV, Nalumaru AS, Kodamanchile V, Varanasi SBVK, Yadlapalli NK, et al. Predicting the Lymphovascular Invasion in Carcinoma Bladder at Transurethral Resection. Cureus n.d.;16:e62595. https://doi.org/10.7759/cureus.62595.
Yoneda K, Utsumi T, Wakai K, Oka R, Endo T, Yano M, et al. Preoperative Clinical Predictors of Lymphovascular Invasion of Bladder Tumors at Transurethral Resection Pathology. Curr Urol 2020;14:135–41. https://doi.org/10.1159/000499247.
Ahmadi N, Shafee H, Moudi E. Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer. Asian J Urol 2024;11:625–32. https://doi.org/10.1016/j.ajur.2023.04.007.
Jancke G, Rosell J, Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J Urol Nephrol 2011;45:388–92. https://doi.org/10.3109/00365599.2011.590995.
Nepple KG, O’Donnell MA. The optimal management of T1 high-grade bladder cancer. Can Urol Assoc J 2009;3:S188–92.
Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol 2024;211:533–8. https://doi.org/10.1097/JU.0000000000003846.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 2022;81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010.
Aminoltejari K, Black PC. Radical cystectomy: a review of techniques, developments and controversies. Transl Androl Urol 2020;9:3073081–3073081. https://doi.org/10.21037/tau.2020.03.23.
Diamant E, Roumiguié M, Ingels A, Parra J, Vordos D, Bajeot A-S, et al. Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer. Cancers 2022;14:3797. https://doi.org/10.3390/cancers14153797.
Li G, Song H, Wang J, Bao Y, Niu Y. Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer. Sci Rep 2016;6:27586. https://doi.org/10.1038/srep27586.
Brassart C, Coutte A, Wallet J, Meyer E, Benyoucef A, Mnif H, et al. Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Cancer/Radiothérapie 2024;28:657–66. https://doi.org/10.1016/j.canrad.2024.05.005.
Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, et al. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. Cancers 2023;15:1937. https://doi.org/10.3390/cancers15071937.
Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus 2023;15:e40962. https://doi.org/10.7759/cureus.40962.
Liu S, Yao Y, Guan F, Sun L, Zhang G. Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Dis Markers 2022;2022:8493519. https://doi.org/10.1155/2022/8493519.
Lavallee E, Sfakianos JP, Mulholland DJ. Tumor Heterogeneity and Consequences for Bladder Cancer Treatment. Cancers 2021;13:5297. https://doi.org/10.3390/cancers13215297.
Cao J, Zhao X, Zhong Z, Zhang L, Zhu X, Xu R. Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Sci Rep 2016;6:35214. https://doi.org/10.1038/srep35214.
Avallone MA, Sack BS, El-Arabi A, Charles DK, Herre WR, Radtke AC, et al. Ten-Year Review of Perioperative Complications After Transurethral Resection of Bladder Tumors: Analysis of Monopolar and Plasmakinetic Bipolar Cases. J Endourol 2017;31:767–73. https://doi.org/10.1089/end.2017.0056.
- Abstract Viewed: 189 times
- 8655/pdf Downloaded: 37 times